Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study

Table 3 Logistic regression analysis of the factors affecting the persistence of hepatitis B viral-deoxyribonucleic acid > 2000 IU/mL

Factors	OR (95%CI)	P value
Age	1.01 (0.91, 1.89)	0.762
Gender (male)	1.86 (0.98, 2.29)	0.289
BMI	0.98 (0.71, 1.38)	0.891
ALT	1.78 (0.78, 1.98)	0.871
AST	1.45 (0.89, 1.87)	0.091
Albumin	0.88 (0.67, 0.92)	0.421
HBV DNA	1.23 (0.87, 1.89)	0.213
Fibrosis score > F2	3.68 (0.32, 16.89)	0.011
Stiffness (FibroScan)	0.91 (0.87, 1.03)	0.367
HBsAg at the end of NUC therapy	2.89 (0.87, 8.45)	0.228

OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: Hepatitis B viral; DNA: Deoxyribonucleic acid; HBsAg: Hepatitis B surface antigen; NUC: Nucleos(t)ide analogues.